For example, in the phase three clinical trial of the antisense oligonucleotide tofersen for SOD1-ALS (see below), a reduction in plasma NFL levels preceded a significant clinical efficacy at 12-month extension, although no improvement in the primary outcome at 6 months was observed [228]. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.